Clinical Impact of Next Generation Flow MRD in Multiple Myeloma

Join experts and healthcare professionals for an insightful online event focusing on the clinical impact of Next Generation Flow Minimal Residual Disease (MRD) assessment in Multiple Myeloma. Scheduled for June 30, 2026, this event will delve into the latest advancements in MRD detection techniques and their implications for treatment decisions and patient outcomes. Attendees will have the opportunity to engage with thought leaders in the field, explore case studies, and discuss the future of MRD monitoring in clinical practice. This event promises to enhance understanding and application of cutting-edge technologies in the management of Multiple Myeloma.